Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wouldn't look for any product royalties in a years' time, but I think there's a good chance of income from their target validation service, or from excess production of DNA when their expanded lab facilities are up & running. Later in '05 there should also be income from a large pharma for the rights for Simplevir( prior to phase III). Phanuel, if you believe rumors, looks to be a fading star. Just hope it doesn't become a thorn. Additional equity funding will happen when and if they need it. Other board members may have differing opinions.
More like a year and a half if you bought at .14.
Good timing though!
Woody, sounds like you like it fast 'n loose if you're into a diamond stock traded on the Pinks! Have you established a position in CYGX yet? If not, you couldn't be in at a better time, IMO.
Relax. A very small percentage of experimental drugs that enter Phase I make it to market. This of course applies to CYGX's stuff as well. A topical treatment may have different uses than an injectible. Plus CYGX has many other irons in the fire too.
With this punky volume, they'll take it down again at the close,unless there is a PR on its way.
CD, sorry about your mom. That breast stuff is terrible. Women think they're cured and it pops up years later out of the blue. It's another area where CYGX has great potential.
As for stem cell research, Reeve's death may be timely in bringing this issue to the forefront. If our politicians put up blocades to progress in this area, other countries are going to run right by us. Its a touchy issue, just like abortion.
Apparently he had a blood born sepsis from pressure sores, which would have developed at home, or wherever he was being cared for. The sepsis subsequently affected his heart. Most quads whose cord injury is as high as his don't live as long as he did, but certainly CYGX's treatment for sepsis would have been of significant benefit.
Downr, agree with all you say re funding. But not all applies in CYGX's case. Banks will only extend a line of credit against an asset. CYGX has almost no assets...just some lab equipment and one patent. Doubt they could get a LOC against this. As for grants, they're constantly seeking them, with modest success. I know directly from Malcomb that they are doing this. Grants, however, are usually earmarked for a specific line of research, and don't do much to help broadbased development. Doing PP's is a third method, and with the stock price so low, this would be very dilutive for all shareholders, which we don't want. A fourth method is licensing deals. They'll pay very little (as with Phanuel)if done too early, when the science is unproven. That's why it's prudent to hang in there as long as possible before inking a deal. Getting Simplevir through phase I and II, assuming the results are good, gives management leverage to really mine some gold from a major drug company, rather than a few pennies from some Texas good old boys.
Are we in for a weekend of hot air and unsubstianted claims from pp? I hope not. No CFO or CEO would deliberately provoke a suit by an outright abrogation of a contract when there is so much at stake. Why win big in the market only to lose in the court room? Remember, no one on the outside knows the current status of the agreement. pp talks like he does, but offers no documentation or evidence. I personally think we will see some outside revenue announced in the next 4 to 6 weeks that will allow less urgency in attracting outside investment capital. The management doesn't want their holdings diluted any more than we do, so they will wait until the money is really needed. The science is being developed based on accepted standards of verifiable scientific research. It doesn't make sense for a management team to be any less honorable.
Same here. I have 25-30K purchased @.25. May trade some of my $.72 shares that I've held over a year, if we get a nice run.
Is this the lull before the storm?
I hope this current situation with Phanuel provides the opportunity to dissolve the partnership(without subsequent lawsuits). It seems like financing is coming soon, and right now we don't need the money. Selling off the Indian and Chinese rights at some point in the future will bring in a lot more than they probably got from Phanuel.
Taton, any comment on the science behind this new patent application? Seems this is much bigger than "just" a way to identify new anti-bacterials (big enough in itself). If this new identification process is faster, easier, cheaper, or more accurate than the current state of the art, it should open up tremendous new contract possibilities. Let's go for the anti-tuberculine strand now!
Agree with your point re the FDA. Where/when did Malcomb make this statement?
Picked up another 5K at .235. Gotta stop sometime...
I happened to notice a BB company (IIIN) that applied for NASDAQ listing Aug 8. 04, and received it's approval today, and it will start trading tomorrow. Process was a lot faster than I thought it would be. Course we got to get to the minimum price first and stay there or above for how long? 90 days?
My guess on sequence...b-a-c
My guess on PPS 12/31/04: a buck.
Anybody else still buying? Added another 6K near the close.
Ameritrade ticks me off though. On electronic funds transfer, they will let you buy listed stocks right away, but you have to wait 5 days before you can buy OTCBB's
TB is an entirely different type ("acid-fast")of bacterium that does not respond to typical antibiotics. It would require it's own anti-sense approach.
I've e-mailed Malcomb about this in the past, but I can't remember if I got a response. TB would be a great target, since most cases are pulmonary, ideally suited for aerosol delivery, and the current treatment is not very effective, and it's developing many resistant strains. There are so many potential targets that I think they just don't have the staff to go after everything. Seems like something the Gates Foundation would be willing to support.
Insiders are allowed to buy their own company's stock as long as they declare it.
Why did SI's post get deleted?
Malcomb's been saying all along that finances are not a problem. I have a feeling there is new income coming from outside clients, and that the investment bank financing is essentially a done deal. What are the chances that we will get line of credit type financing, rather than private placements?
Thalio, go back to CYGX and comment on Taton's posts #10728,29, and 30. john
OT...Luck, can't keep up a CYGX conversation on this board.
Check out the CYGX board sometime. What do you do besides being a housewife?
Several potential problems with Phico's approach. One, they are injecting a "foreign protein". Foreign proteins always have the potential of a serious allergic reaction. Second, there's no reason MRSA or VRSA can't quickly mutate into a new resistant strain, because there's nothing really new in Phico's approach; it's just another new antibiotic. Third, viral vectors, if that's what they're using, have been discussed by MS in the past, and discounted as inferior.
Anybody see today's Reader article by Don Bauder?
OT...Luck, you'll be doing yourself a big favor if you take a serious look at CYGX. The science is very difficult to grasp, but just an inkling of understanding will boggle your mind as to their potential. Several doctors here where I work own large #'s of shares, and a Nobel laureate next door has commented very favorably on their approach. STD's are only a small part of their repetoir. If they were flim-flam, they would not be publishing articles in peer-reviewed journals.
They're getting very clost to an IND for their Herpes treatment(only 1/4 of the US population has it), and the sepsis IND will come a few months later. The CYGX board is very good here. Go back to the early posts of a year ago for some good educational stuff.
Maybe the guys in Texas DO read this board:
Posted by: HANUMAN
In reply to: arnold who wrote msg# 10192 Date:8/10/2004 12:54:16 PM
Post #of 10676
I still think a once monthly shareholder update via e-mail would be most helpful, and a lot cheaper than the radio "interviews", ie paid advertising. To a certain extent it's all preaching to the choir. But doing the shareholder updates would eliminate the need to respond to all the individual e-mails the company receives.
I was particularly impressed that the Baylor patent noted the liposome package allowed for parenteral delivery, which presumably includes both IM and IV routes. Thus all types of infectious processes as well as neoplastic lesions could be addressed. Do the liposomes also cross the blood-brain barrier? If so, then Alzsheimer's could also be a target.
holy, we're working with BioZone, which appears to have no connection to Baylor, or this particular inventor. However, the technology described in this patent seems to be a perfect fit for our needs, and with our established relationship with Baylor and the close physical opportunity, it would seem likely there would be some connection. I e-mailed Chen about this, but I doubt if I'll hear back. The PhD who received the patent has at least 3 others pending, and she's not even a full professor.
Did a little more looking. The patent holder is at Baylor!
We must be working with this particular delivery system. Amazing how versatile it is if you read into the patent a little way.
http://www.bcm.edu/mcb/faculty/templeton.htm
Such a slow day, I started to Google on Yahoo. Found this interesting patent very recently issued to a Houston inventor, which appears to be another delivery system for anti-sense therapeutics. Any comments Taton?
http://www.pharmcast.com/Patents100/Yr2004/Aug2004/080304/6770291_Liposomes080304.htm
None of my business, but if you want a biotech that has huge potential, check out CYGX.
ec, I agree with your position. Stick with it. Anything that you might learn, just by inference or otherwise, risks getting distorted by those who like to pump or bash. It may also cause contacts to totally dry up.
EC, add me to your e-mail list. Address is listed in my bio.
Great news Neo. Where did you get that from? Maybe that'll keep Suky on board!
I'm thinking Kendirgi's addition might be to focus more on target validation services, since his brief bio in the PR stated he has experience with expression vectors. With not a lot of cash on hand, this may be his source of salary.
Don't know. Anyone out there? Can it be Googled? Accessible through court documents?
On a broader topic, and I've asked this before, can someone familiar with CYGX back to its origins please write us a history?
Even if AVGI does own animal rights,and wins the court case, presumably this would generate royalty income for CYGX. No??
I fail to see how this would be bad, particularly if the terms are the same as they hope to derrive from other partnering companies. Would like to know what part of the supposed agreement CYGX is contesting.